Therapeutic efficacy and immunological response of CCL5 antagonists in models of contact skin reaction

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Canavese, Miriam ^a   Altruda, Fiorella ^a   Silengo, Lorenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

44 AANA 47 CCL5; CHEMOKINE RECEPTOR ANTAGONIST; CYTOKINE; DEXAMETHASONE; GAG PROTEIN; HAPTEN; MET CCL5; UNCLASSIFIED DRUG; OXAZOLONE; RANTES;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; COMPETITIVE INHIBITION; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HOMOGENATE; IMMUNE RESPONSE; IRRITANT DERMATITIS; KERATINOCYTE; MOUSE; NONHUMAN; PSORIASIS; SKIN INFLAMMATION; SKIN SWELLING; T LYMPHOCYTE; TREATMENT RESPONSE; ANIMAL; CELL CULTURE; CONTACT DERMATITIS; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY;

ANIMALS; CELLS, CULTURED; CHEMOKINE CCL5; DERMATITIS, CONTACT; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; OXAZOLONE;

EID: 77649291549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008725     Document Type: Article

References (22)

1. Pastore S, Mascia F, Mariotti F, Dattilo C, Girolomoni G (2004) Chemokine networks in inflammatory skin diseases. Eur J Dermatol 14: 203-8.
2. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, et al. (2004) Intereference with Heparin Binding and Oligomerization Creates a novel Anti-Inflammatory Strategy targeting the Chemokine System. The J of Immunology 173: 5776-85.
3. Proudfoot AE, Fritchley S, Borlat F, Shaw JP, Vilbois F, et al. (2001) The BBXB Motif of CCL5 Is the Principal Site for Heparin Binding and Controls Receptor Selectivity. The Journal of Biological Chemistry 276: 106-20.
4. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, et al. (2003) Distinct patterns of gene expression in the skin lesion of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 112: 1195-1202.
5. Asadullah K, Volk HD, Sterry W (2002) Novel immunotherapies for psoriasis. TRENDS in Immunology 23: 47-53.
6. Schön MP, Ruzicka T (2001) Psoriasis: the plot thickens. Naure Immunology 2(2): 91.
7. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ (1994) Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144: 820-8.
8. Gillitzer R, Wolff K, Tong D, Müller C, Yoshimura T, et al. (1993) MCP-1 mRNA expression in basal keratinocytes of psoriatic lesion. J Invest Dermatol 101: 127-31.
9. McKay IA, Leigh IM (1995) Altered Keratinocyte Growth and Differentiation in Psoriasis. Clinics in Dermatology 13: 105-114.
10. Dahl MV (1988) Chronic irritant contact dermatitis: mechanism, variables, and differentiation from others forms of contact dermatitis. Adv Dermatol 3: 261-75.
11. Löffler H, Effendy I, Happle R (2000) Irritant contact dermatitis. Hautarzt 51(3): 203-15.
12. Proudfoot AE, Buser R, Borlat F, Alouani S, Soler D, et al. (1999) Amino-terminally Modified CCL5 Analogues Demonstrate Differential Effects on CCL5 Receptors. J Biol Chem 274(45): 32478-85.
13. Matsui M, Weaver J, Proudfoot AE, Wujek JR, Wei T, et al. (2002) Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-CCL5. Journal of Neuroimmunology 128: 16-22.
14. Grabbe S, Steinert M, Mahnke K, Schwartz A, Luger TA, et al. (1996) Dissection of Antigenic and Irritative Effects of Epicutaneously Applied Haptens in Mice. Evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis. J Clin Invest 98(5): 1158-64.
15. Proudfoot AE (2002) Chemokine receptors: Multifaceted Therapeutic Targets. Nature Rev Immunol 2(2): 106-115.
16. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, et al. (1996) Extention of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 271(5): 2599-2603.
17. Texeira MM, Wells TNC, Lukacs NW, Proudfoot AE, Kunkel SL, et al. (1997) Chemokine-induced Eosinophil Recruitment. J Clin Invest 100(7): 1657-1666.
18. Akahira-Azuma M, Szczepanik M, Tsuji RF, Campos RA, Itakura A, et al. (2004) Early delayed-type hypersensitivity eosinophil infiltrates depend on T helper 2 cytokines and interferon-c via CXCR3 chemokines. Immunology 111: 306-317.
19. Kapuscinska R, Wysocka J, Niczyporuk W, Ratomski K (2004) Cytofluorimetric assay for evaluation of CD16 receptor expression and myeloperoxidase (MPO) activity of neutrophils in patients with psoriasis vulgaris treated with PUVA. Wiad Lek 57(11-12): 599-602.
20. Elsner J, Petering H, Kimmig D, Wells TN, Proudfoot AE, et al. (1999) The CC chemokine receptor antagonist met-RANTES inhibits eosinophil effector functions. Int Arch Allergy Immunol 118(2-4): 462-5.
21. Johnson Z, Schwarz M, Power CA, Wells TN, Proudfoot AE (2005) Multifaceted strategies to combat disease by interference with the chemokine system. TRENDS in Immunology 26(5): 268-274.
22. Glass WG, Hickey MJ, Hardison JL, Liu MT, Manning JE, et al. (2004) Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J Immunol 172(7): 4018-25.